Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

Li, Hongshuai; Yang, Lili; Zhang, Mingyi; Cheng, Ke; Chen, Ye; Liu, Jiyan

doi:10.3389/fonc.2020.548867

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pyrotinib, an irreversible pan-HER TKI targeting HER2, EGFR, and HER4, was approved in China in 2018 for the treatment of HER2-positive recurrent or metastatic breast cancer and has shown anti-tumor effects in other solid tumors such as lung and gastric cancers[ 79 ]. Li et al [ 80 ] found that pyrotinib monotherapy could be effectively used for salvage therapy in HER2-amplified mCRC patients who have developed resistance to trastuzumab and lapatinib (Tykerb), based on which Chang et al [ 81 ] conducted the HER2-FUSCC-G study. HER2-FUSCC-G is a single-center open-label, non-randomized, ongoing, phase II study with three cohorts to evaluate the efficacy of pyrotinib in patients with HER2-positive gastrointestinal cancer refractory to standard treatment.…”

Section: Her-2-amplified Mcrcmentioning

confidence: 99%

Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer

Zhou,

Wu,

2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

More than 1.9 million new colorectal cancer (CRC) cases and 935000 deaths were estimated to occur worldwide in 2020, representing about one in ten cancer cases and deaths. Overall, colorectal ranks third in incidence, but second in mortality. More than half of the patients are in advanced stages at diagnosis. Treatment options are complex because of the heterogeneity of the patient population, including different molecular subtypes. Treatments have included conventional fluorouracil-based chemotherapy, targeted therapy, immunotherapy, etc. In recent years, with the development of genetic testing technology, more and more targeted drugs have been applied to the treatment of CRC, which has further prolonged the survival of metastatic CRC patients.

show abstract

Section: Her-2-amplified Mcrcmentioning

confidence: 99%

Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer

Zhou,

Wu,

2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Multiple clinical trials focusing on HER2-targeted therapies have resulted in exciting outcomes in the treatment of various solid tumors with abnormal expressions of HER2 [9][10][11]. As a robust irreversible EGFR/HER2 dual tyrosine kinase inhibitor, pyrotinib has shown remarkable responses in many advanced cancers even with previously failed EGFR/HER2 targeted treatments [12,13]. Therefore, it is worth exploring whether pyrotinib has the equivalent e cacy in advanced OSCC.…”

mentioning

confidence: 99%

Anti-tumor Efficacy and Potential Mechanism of Pyrotinib in Locally Advanced Oral Squamous Cell Carcinoma

Zhou,

Wang,

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The resistance to epidermal growth factor receptor (EGFR) target therapy is common in advanced oral squamous cell carcinoma (OSCC). Meanwhile human epidermal growth factor receptor 2 (HER2) plays an important role in the progression of multiple solid tumors and induces resistance to EGFR target treatment. However, the expression status and the clinical significance of HER2 in OSCC is still controversial. Pyrotinib has shown promising activity as a novel EGFR/HER2 dual inhibitor, in many advanced cancers, but its efficacy in OSCC has not been determined. Methods 57 locally advanced de novo OSCC patients admitted into a single tertiary referral hospital were enrolled in this study with the approval of the ethics committee. Through tissue microarray analysis of the primary tumors and paired para-tumor oral mucosa, the relationship between the expression levels of HER2 and the prognosis of OSCC patients had been investigated. To complement these findings, the antitumor efficacy of pyrotinib in OSCC was retrieved in vitro and in vivo. The main downstream of HER2 was evaluated by western blotting in OSCC cell lines and xenograft tumors to explore the potential mechanism of pyrotinib. Results This study revealed the primary tumor of OSCC had higher HER2 expression levels. Through Kaplan-Meier analysis, OSCC patients with high HER2 expression had poor overall survival (P < 0.014) and poor disease free survival (P < 0.042). In vitro, pyrotinib suppressed the proliferation, colony formation and migration of OSCC cells. Pyrotinib also promoted apoptosis of OSCC cells and induced cell cycle arrest. This study also confirmed that pyrotinib was able to inhibit the occurrence and development of OSCC effectively in vivo. Furthermore, western blotting revealed that pyrotinib suppressed OSCC by inhibiting the phosphorylation of HER2, AKT and ERK in vitro and in vivo. Conclusions This is the first study to exhibit the anti-OSCC effects of pyrotinib in vitro and in vivo, and demonstrated pyrotinib inhibited OSCC cells by inducing apoptosis via the HER2/ AKT and ERK pathway. The result of this study also indicated locally advanced OSCC patients might benefit from HER2 assay and EGFR/HER2 dual inhibit treatment.

show abstract

Multiple drugs

2021

Reactions Weekly

View full text Add to dashboard Cite

Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

Cited by 4 publications

References 22 publications

Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer

Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer

Anti-tumor Efficacy and Potential Mechanism of Pyrotinib in Locally Advanced Oral Squamous Cell Carcinoma

Multiple drugs

Contact Info

Product

Resources

About